No.	M/0	Label	Type	Size	Name	Description
1	M				SÚKL code	Code of the medicinal product ("MP") allocated by SÚKL to the presentation of the MP as part of the marketing authorisation (MA) of the MP, or allocated to a non-authorised MP included in a specific therapeutic programme ("STP"), or allocated to food for special medical purposes ("FSMP")
2	M				Name of medicinal product	Name of the MP or FSMP
3	M				Medicinal product specification	MP's name supplement, which clearly defines the presentation of the MP, consisting of an integration of its route of administration, pharmaceutical form, pack size and strength. This item of the List is further detailed in the CESTA, FORMA, BALENI and SILA fields
4	M				Route of administration	Route of administration
5	M				Pharmaceutical form	Pharmaceutical form
6	M				Pack	Pack size
7	M				Strength	The strength of the MP, i.e. the contents of active substances expressed qualitatively pro rata to a unit of dose, volume or weight, depending on the pharmaceutical form.
8	M				Packaging	The immediate packaging of the MP, i.e. form of packaging that is in immediate contact with the MP.
9	O				MA holder	Marketing authorisation holder's abbreviation. A common implemental index is available for the DRZ and ZEM DRZ fields.
10	O				Holder's country	An abbreviation of the country of the MA holder's registered office; abbreviation of the country of manufacturer's/importer's registered office for MPs included in STPs and for FSMPs. A common implemental index is available for the DRZ and ZEM DRZ fields.
11	O				MA number	Marketing authorisation number, which identifies a group of presentations of an MP for which the MA has been issued.
12	O				Parallel import ID	The identification number of parallel import, which is associated with the respective reference product as per MA number; usually in the following format: PI/xxx/tyty
13	O				MA type	Marketing authorisation (type of MA – national, MRP, DCP, via centralised procedure, adopted MA, parallel import).
14	M				MA status	Status of the marketing authorisation, the basic values being as follows: **R** – Authorised medicinal product **B** – Following an implemented variation thereto, a product may be marketed for the period of 6 months and used until its expiry date, not exceeding the MA expiry date **Q** – The product could be marketed for the period of 6 months following an implemented code conversion and may be used until its expiry date not exceeding the MA expiry date **F** – Specific therapeutic programme authorised by the Ministry of Health of the Czech Republic upon SÚKL's recommendation **P** – Foods for special medical purposes **STAVREG status value implemental index is available for the S_REG field.**
15	M				Price regulation type	Type of price regulation – applicable values: **MCV** – Maximum ex-factory price; **OP** – Regulation of the profit margin; the factory price is not subject to regulation under the Health Ministry's Price Regulation.
16	O				Ex-factory price	Maximum ex-factory price of the MP/FSMP; depending on the TCR field value, this may be either the maximum ex-factory price, or the announced ex-factory price.

17	O				Ex-factory price legal basis	Legal basis for setting the MP/FSMP ex-factory price; applicable values: **S** – Established or amended via administrative procedure under Act No 48/1997 Coll., as amended as of January 1, 2008 **G** – Price set *ex lege*, i.e. set under Section 39g(9) of Act No 48/1997 Coll. **P** – Temporary *ex lege* price decrease, i.e. a temporary price decrease set forth by the law **M** – Price set by the Czech Finance Ministry under Act No 265/1991 Coll. and Act No 526/1990 Coll., as amended before December 31, 2007 **N** – The stated price is the *ex lege* established or amended price at which the applicant may market the MP or the FSMP, if no decision on their applications has been taken within the timelines set out by Act No 48/1997 Coll., as amended. This price equals the price stated in the application for maximum price determination or change thereof. This price shall be effective until an effective decision is issued in the matter. **O** – Announced ex-factory price. **R** – The price limit is based on the last announced ex-factory price where the maximum price of an MP, reclassified as an MP subject to maximum price regulation under a price decision of the Czech Health Ministry, has not been set previously. **X** – Decision on the amount and terms of reimbursement has not become effective, and is preliminarily enforceable.
18	O				Grounds for max. ex-factory price	If the TCR field contains the "MCV" value, this field will contain the file no. of administrative procedure before SÚKL, or has the "MF" value, if the ex-factory price has been set in compliance with legal rules and regulations (MF's price assessment). If the TCR field contains the "OP" value, this field will remain empty.
19	O				Reimbursement	Reimbursement of the medicinal product for the end consumer (JUHR1 plus the maximum profit margin under the price regulation of the Czech Health Ministry, plus VAT).
20	O				Core reimbursement	Reimbursement of the medicinal product set by SÚKL under Section 39g(4) of Act No 48/1997 Coll., or determined under the interim provisions of the "technical amendment"
21	M				Legal basis for core reimbursement	Legal basis for setting the MP/FSMP core reimbursement from health insurance; applicable values: **S** – Established or amended via administrative procedure under Act No 48/1997 Coll., as amended as of January 1, 2008 **A** – *Ex lege* (statutory) reimbursement of MPs that contain an active substance listed in Section 15(4) of Act No 48/1997 Coll., as amended, at the ex-factory price of the least economically demanding presentation of the MP. **P** – Temporary *ex lege* price decrease, i.e. a temporary price decrease set forth by the law **M** – Set by Health Ministry's Decree No 63/2007 Coll.; validity governed by Act No 261/2007 Coll. **1** – Winning bidder of the reimbursement tender (RT) **Q** – Products whose reimbursement is directly affected by the RT but does not equal the reimbursement of the winning bidder of the reimbursement tender **V** – MP is reimbursed within reimbursed care under Section 30 of Act No 48/1997 Coll., as amended (only for vaccines listed in Section 30 of the Act). **The reimbursement may not exceed the price of the least economically demanding presentation of the vaccine**. **O** – Reduction of reimbursement as part of government-approved measure to ensure financial stability of the health insurance system under Section 39i(3) of Act No 48/1997 Coll. **G** – Price set *ex lege*, i.e. set under Section 39g(9) of Act No 48/1997 Coll. **D** – Temporary reimbursement of a highly innovative product under Section 39d of Act No 48/1997 Coll. **X** – Decision on the amount and terms of reimbursement has not become effective, and is preliminarily enforceable.
22	O				Grounds for setting the amount of nucl. r.	Contains the file no. of administrative procedure before SÚKL, or reference to statutory provision, or reference to a Health Ministry Regulation that has set the reimbursement in compliance with the aforementioned legal rules and regulations.

23	O				Reporting limit	Method of reporting MPs/FSMPs to the health insurance company. **A joint LIM status value implemental index is available for the LIM1, LIM2 and LIM3 fields.**
24	O				Prescribing doctor's specialisation	Specification of prescription restriction based on the specialisation of the prescribing doctor. For a single MP/FSMP code it may assume several OME1 values. **A joint OME status value implemental index is available for the OME1, OME2 and OME3 fields.**
25	O				Indication restriction flag	Indication restriction (P). The **DETIND1 implemental index** is available for the indication prescription detail (indication or clinical condition conditioning the reimbursement of the MP/FSMP).
26	O				Full reimbursement flag	The full reimbursement flag may have the following values: I – the least economically demanding presentation of MPs fully reimbursed under the law J – MPs where MFC <= UHR1. Note: Final sales under the Czech Health Ministry's pricing regulations are disregarded. U – MPs fully reimbursed under reimbursement agreements under Section 39c(2)(d) of Act No 48/1997 Coll.
27	O				Temporary reimbursement until	Temporary reimbursement is determined for 24 or, as the case may be, 12 months, and the field contains the expiry date of the temporary reimbursement, provided that the LEG_JUHR1 field contains the D value.
28	O				Percentage reimbursement	The percentage of reimbursement paid by the health insurer, as stipulated by Decree of the Czech Health Ministry.
29	O				Written arrangement on price in public interest	Identification of the maximum price (X) agreed between the health insurer and the MA holder. If the calculated MFC is lower than the agreed maximum price announced by the health insurer, the field will contain the "Y" value.
30	O				Second reimbursement	Second reimbursement of the medicinal product/FSMP set by SÚKL under Section 39b(11) or Section 39d of Act No 48/1997 Coll. for the end consumer (JUHR2 plus the maximum profit margin under the price regulation of the Czech Health Ministry, plus VAT).
31	O				Second core reimbursement	Second core reimbursement of the medicinal product/FSMP set by SÚKL under Section 39b(11) or Section 39d of Act No 48/1997 Coll.
32	O				Legal basis for the second core reimbursement	Legal basis for setting the second MP/FSMP core reimbursement from health insurance; applicable values: **P** – Temporary *ex lege* price decrease, i.e. a temporary price decrease set forth by the law **1** – Winning bidder of the reimbursement tender (RT) **Q** – Products whose reimbursement is directly affected by the RT but does not equal the reimbursement of the winning bidder of the reimbursement tender **O** – Reduction of reimbursement as part of government-approved measure to ensure financial stability of the health insurance system under Section 39i(3) of Act No 48/1997 Coll. **G** – Price set *ex lege*, i.e. set under Section 39g(9) of Act No 48/1997 Coll. **D** – Temporary reimbursement of a highly innovative product under Section 39d of Act No 48/1997 Coll. **Z** – Additional increased reimbursement set out under Section 39b(11) of Act No 48/1997 Coll. **X** – Decision on the amount and terms of reimbursement has not become effective, and is preliminarily enforceable.
33	O				Grounds for setting the second core r.	Contains the file no. of administrative procedure before SÚKL, or reference to statutory provision.
34	O				Second reimbursement reporting limit	Method of reporting the MPs/FSMPs' increased reimbursement to the health insurance company. **A joint LIM status value implemental index is available for the LIM1, LIM2 and LIM3 fields.**

35	O				Prescribing doctor's specialisation	Specification of prescription restriction for the second MP/FSMP reimbursement based on the specialisation of the prescribing doctor. For a single MP/FSMP code it may assume several OME2 values. **A joint OME status value implemental index is available for the OME1, OME2 and OME3 fields.**
36	O				Indication restriction flag	Indication restriction (P). The DETIND2 implemental index is available for the indication prescription detail (indication or clinical condition conditioning the second reimbursement of the MP/FSMP).
37	O				Full reimbursement flag	The full reimbursement flag may have the following values: J – for MPs that are fully reimbursed if MFC <= UHR2. Note: Final sales under the Czech Health Ministry's pricing regulations are disregarded. U – MPs fully reimbursed under reimbursement agreements under Section 39c(2)(d) of Act No 48/1997 Coll.
38	O				Second temporary reimbursement until	Temporary reimbursement is determined for 24 or, as the case may be, 12 months, and the field contains the expiry date of the temporary reimbursement, provided that the LEG_JUHR2 field contains the D value.
39	O				Third reimbursement	Third reimbursement of the medicinal product/FSMP set by SÚKL under Section 39d of Act No 48/1997 Coll. for the end consumer (JUHR3 plus the maximum profit margin under the price regulation of the Czech Health Ministry, plus VAT).
40	O				Third core reimbursement	Third core reimbursement of the medicinal product/FSMP set by SÚKL under Section 39d of Act No 48/1997 Coll.
41	O				Legal basis for the third core reimbursement	Legal basis for setting the third MP/FSMP core reimbursement from health insurance; applicable values: **P** – Temporary *ex lege* price decrease, i.e. a temporary price decrease set forth by the law **O** – Reduction of reimbursement as part of government-approved measure to ensure financial stability of the health insurance system under Section 39i(3) of Act No 48/1997 Coll. **D** – Temporary reimbursement of a highly innovative product under Section 39d of Act No 48/1997 Coll. **X** – Decision on the amount and terms of reimbursement has not become effective, and is preliminarily enforceable.
42	O				Grounds for setting the third core r.	Contains the file no. of administrative procedure before SÚKL.
43	O				Third reimbursement reporting limit	Method of reporting the MP/FSMP's third reimbursement to the health insurance company. **A joint LIM status value implemental index is available for the LIM1, LIM2 and LIM3 fields.**
44	O				Prescribing doctor's specialisation	Specification of prescription restriction for the third MP/FSMP reimbursement based on the specialisation of the prescribing doctor. For a single MP/FSMP code it may assume several OME2 values. **A joint OME status value implemental index is available for the OME1, OME2 and OME3 fields.**
45	O				Indication restriction flag	Indication restriction (P) for the MP/FSMP's third reimbursement. The DETIND3 implemental index is available for the indication prescription detail (indication or clinical condition conditioning the third reimbursement of the MP/FSMP).
46	O				Full reimbursement flag	The full reimbursement flag may have the following values: J – for MPs that are fully reimbursed if MFC <= UHR3. Note: Final sales under the Czech Health Ministry's pricing regulations are disregarded. U – MPs fully reimbursed under reimbursement agreements under Section 39c(2)(d) of Act No 48/1997 Coll.
47	O				Third temporary reimbursement until	Temporary reimbursement is determined for 24 or, as the case may be, 12 months, and the field contains the expiry date of the temporary reimbursement.
48	O				Reference group	The applicable reference group of the MP where the MP has been allocated a reference group by SÚKL when establishing the amount and terms of reimbursement; it shall comprise of the applicable therapeutic group (TS), separator (/), sequence of the subgroup of products that are similar or that can cause confusion in the RS (RS_P); RS stipulated by a Decree of the Czech Health Ministry under authority set out in Section 39c(1) of Act No 48/1997 Coll.

49	O				Therapeutic group	The applicable therapeutic group of the MP/FSMP if it has been allocated a therapeutic group by SÚKL when establishing the amount and terms of reimbursement; TS stipulated by a Decree of the Czech Health Ministry under authority set out in Section 39c(1) of Act No 48/1997 Coll.
50	O				TS subgroup	The applicable subgroup of products that are similar or that can cause confusion within the TS of the MP/FSMP where an RS has been allocated by SÚKL when establishing the amount and terms of reimbursement; TS_P stipulated by Decree of the Czech Health Ministry under authority set out in Section 39c(1) of Act No 48/1997 Coll.
51	O				Full ATC	Anatomical therapeutic chemical group **An ATC implemental index is available for the ATC field.**
52	O				MA effective date	Effective date of the marketing authorisation
53	O				MA expiry date	Expiry date of the marketing authorisation, unless unlimited validity has been granted pursuant to Section 34 of the Act on Pharmaceuticals.
54	O				Unlimited MA validity	Field to be completed (X) where unlimited validity of the marketing authorisation applies.
55	O				Placement on market	Date of initial placement of supplies of the medicinal product on the market or reinstitution thereof, to be reported by the MA holder in compliance with Section 33 of the Act on Pharmaceuticals.
56	O				Supply termination	Date of termination or discontinuation of supplies of the medicinal product onto the market, to be reported by the MA holder in compliance with Section 33 of the Act on Pharmaceuticals
57	O				Amount of active substance in DDD	Defined daily dose - the amount of active substance – information as per WHO
58	O				Unit of active substance in DDD	Defined daily dose – unit – information as per WHO
59	O				DDD count in MP pack	The number of defined daily doses in a pack - where DDD has been established by WHO
60	O				Usual daily therapeutic dose for reimbursement	The usual daily therapeutic dose for reimbursement
61	O				Unit of active substance amount in ODTD1	The usual daily therapeutic dose for reimbursement – unit for ODTD1
62	O				Number of ODTD1 in MP pack	Number of usual daily therapeutic doses in a pack for ODTD1.
63	O				Usual daily therapeutic dose for the second reimbursement	The usual daily therapeutic dose for the second reimbursement
64	O				Unit of active substance amount in ODTD2	The usual daily therapeutic dose for the second reimbursement – unit for ODTD2
65	O				Number of ODTD2 in MP pack	Number of usual daily therapeutic doses in a pack for ODTD2.

66	O				Usual daily therapeutic dose for third reimbursement	The usual daily therapeutic dose for the third reimbursement
67	O				Unit of active substance amount in ODTD3	The usual daily therapeutic dose for the second reimbursement – unit for ODTD3
68	O				Number of ODTD3 in MP pack	Number of usual daily therapeutic doses in a pack for ODTD3.
69	O				Reimbursement for ODTD1	Basic reimbursement of the active substance or reference group or, as the case may be, the MP in case of temporary payment for ODTD1, if set by SÚKL under Section 39c(1) and (2) or, as the case may be, Section 39d of Act No 48/1997 Coll.
70	O				Grounds for setting EKV1	Contains the file no. of administrative procedure before SÚKL.
71	O				Reimbursement for ODTD2	Second reimbursement of the active substance or pseudo-reference group or, as the case may be, the MP in case of temporary payment for ODTD2, if set by SÚKL under Section 39b(11) or, as the case may be, Section 39d of Act No 48/1997 Coll.
72	O				Grounds for setting EKV2	Contains the file no. of administrative procedure before SÚKL.
73	O				Reimbursement for ODTD3	Third reimbursement of the MP for ODTD3, if set by SÚKL under Section 39d of Act No 48/1997 Coll.
74	O				Grounds for setting EKV3	Contains the file no. of administrative procedure before SÚKL.
75	O				CP validity	Date of change to the ex-factory price.
76	M				UHR validity	Date of change to the determined amount and terms of reimbursement.
77	M				Eligible extra payment	Eligible extra payment for UHR1 under a communication of the Czech Health Ministry, stipulated in compliance with Section 16b(1) of Act No 48/1997 Coll.
78	M				Limit eligibility symbol	A flag of the category of the pharmaceutical (non-eligibility for the limit) under a communication of the Czech Health Ministry, stipulated in compliance with Section 16b(1) of Act No 48/1997 Coll.The **NEZAP** implemental index is available for the NEZAP 1 field.
79	O				Eligible extra payment calculation base	Contains the "X" value only for MPs that form the basis for the calculation of the eligible extra payment under Section 16b(1) of Act No 48/1997 Coll.
80	O				Eligible extra payment for 2nd reimbursement	Eligible extra payment for UHR2 under a communication of the Czech Health Ministry, stipulated in compliance with Section 16b(1) of Act No 48/1997 Coll.
81	O				Limit eligibility symbol	A flag of the category of the pharmaceutical (non-eligibility for the limit) under a communication of the Czech Health Ministry, stipulated in compliance with Section 16b(1) of Act No 48/1997 Coll.The **NEZAP** implemental index is available for the NEZAP 2 field.
82	O				Eligible extra payment for 3rd reimbursement	Eligible extra payment for UHR3 under a communication of the Czech Health Ministry, stipulated in compliance with Section 16b(1) of Act No 48/1997 Coll.

83	O				Limit eligibility symbol	A flag of the category of the pharmaceutical (non-eligibility for the limit) under a communication of the Czech Health Ministry, stipulated in compliance with Section 16b(1) of Act No 48/1997 Coll. The **NEZAP** implemental index is available for the NEZAP 3 field.
84	O				Method of dispensing	Classification of the product for dispensing: **F** – without medical prescription, **O** – restricted OTC, **R** – on medical prescription **V** – reserved medicinal product The method of dispensing foods for special medical purposes is not specified: SÚKL is not authorized to make decisions on the method used to dispense foods for special medical purposes.
85	O				Economically least demanding vaccine presentation	The amount of reimbursement for the economically least demanding presentation of vaccines reimbursed under Section 30 of Act No 48/1997 Coll., as amended.
86	O				Final price	Final price – price for the final consumer (ex-factory price plus the maximum profit margin under the Health Ministry's price regulation and VAT). If the health insurer and the MA holder concluded an agreement on the maximum agreed price of the product or assumed a valid obligation not to exceed the price assumed in a price tender under Section 39 of Act No 48/1997 Coll., as amended, as amended before the technical amendment, the agreed price, lower than the MFC, will be put in this field. If the calculated MFC is lower than the agreed maximum price announced by the health insurer or the price assumed in the pricing tender, the calculated MFC value will be put in this field.
87	O				Vaccine doses	Number of vaccine doses in pack.
88	O					Reserve field 1
89	O					Reserve field 6
90	O					Reserve field 7
91	O					Reserve field 8
92	O					Reserve field 9
93	O					Reserve field 10
94	O					Reserve field 11
95	O					Reserve field 12
96	O					Reserve field 13
97	O					Reserve field 14
98	O					Reserve field 15
99	O					Reserve field 16
100	O					Reserve field 17
101	O					Reserve field 18
102	O					Reserve field 19
103	O					Reserve field 20
104	O					Reserve field 21
105	O					Reserve field 22
106	O					Reserve field 23

107	O					Reserve field 24
108	O					Reserve field 25
109	O					Reserve field 26
110	O					Reserve field 27
111	O					Reserve field 28
112	O					Reserve field 29
113	O					Reserve field 30
114	O					Reserve field 31
115	O					Reserve field 32
116	O					Reserve field 33
117	O					Reserve field 34
118	O					Reserve field 35
119	O					Reserve field 36
120	O					Reserve field 37
121	O					Reserve field 38
122	O					Reserve field 39

Code page: 1250 WIN CZ
Field separator: "|"
The "M/O" column identifies mandatory and optional fields of the List.
The "Type" column identifies the format of the fields as follows: "C" – character attribute
"N" – numeric attribute
"D" – date in the "ddmmyyyy" format
The "Size" column identifies the scope of the fields. The format of numerical fields is identified as "x,y" ("x" numbers, incl. the decimal point, of which "y" decimal numbers).